Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Gut microbial dysbiosis and altered metabonomics have been implicated in the pathogenesis of Crohn’s disease (CD). The aim of our study was to characterize the gut microbiome structure and metabolic activities in pediatric CD patients with different clinical outcomes after infliximab (IFX) therapy. Fecal samples were collected from 20 healthy children and 29 newly diagnosed pediatric CD patients. 16S rRNA/ITS2 gene sequencing and targeted metabolomics analysis were applied to profile the gut bacterial microbiome, mycobiome, and metabolome, respectively. Pediatric CD patients exhibited lower relative abundances of short-chain fatty acids (SCFAs)-producing bacteria including Faecalibacterium, Clostridium clusters IV and XIVb, Roseburia, and Ruminococcus, which were correlated with reduced fecal levels of SCFAs. Decreased unconjugated bile acids (BAs) pool size and a lower unconjugated/conjugated BAs ratio were associated with reduced relative abundances of Bifidobacterium and Clostridium clusters IV and XIVb which contain bile salt hydrolases (BSH) genes. IFX treatment enriched the BSH-producing bacteria in CD subjects, which may explain a decreased level of conjugated BAs and an increase in unconjugated BAs as well as the unconjugated/conjugated BAs ratio. Furthermore, a sustained response (SR) of IFX therapy was associated with higher abundances of Methylobacterium, Sphingomonas, Staphylococcus, and Streptococcus, and higher fecal concentrations of amino acids, including L-aspartic acid, linoleic acid, and L-lactic acid at baseline. Our study suggests that the effects of IFX might be partially mediated by enriching bacteria taxa that producing SCFAs and BSH thereby inhibiting inflammation and restoring the BA metabolism. Some fecal bacteria and metabolites may be predictive of outcomes of IFX therapy for pediatric CD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., Gratadoux, J.-J., Blugeon, S., Bridonneau, C., Furet, J.-P., Corthier, G., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804812105 · Cited by 4,413 · cited 1×
“The fecal level of SCFAs and gut bacteria ferment fibers that produce SCFAs were typically reduced in IBD patients.(40,41) As expected, our data demonstrated that all the major SCFAs including acetic acid, butyric acid, propanoic acid, and some SCFA-producing bacteria taxa, such as genera Faecalibacterium and Rose bur…”
ResultThe Treatment-Naive Microbiome in New-Onset Crohn’s Disease
Gevers, D., Kugathasan, S., Denson, L. A., Vázquez-Baeza, Y., Van Treuren, W., Ren, B., Schwager, E., Knights, D., Song, S. J., Yassour, M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.02.005 · Cited by 3,220
Topping, D. L., & Clifton, P. M. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.3.1031 · Cited by 3,091
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Gut microbiome structure and metabolic activity in inflammatory bowel disease
Franzosa, E. A., Sirota-Madi, A., Avila-Pacheco, J., Fornelos, N., Haiser, H. J., Reinker, S., Vatanen, T., Hall, A. B., Mallick, H., McIver, L. J., et al. (2018) · Nature Microbiology · doi:10.1038/s41564-018-0306-4 · Cited by 1,995 · cited 1×
“Previous metabolomics studies have revealed specific metabolic signatures that discriminate between IBD patients and healthy individuals.(33,34) However, these studies were heterogeneous for including different subtypes of IBD and using different metabolomics approaches.”
BackgroundMachiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., et al. (2014) · Gut · doi:10.1136/gutjnl-2013-304833 · Cited by 1,904 · cited 1×
“The fecal level of SCFAs and gut bacteria ferment fibers that produce SCFAs were typically reduced in IBD patients.(40,41) As expected, our data demonstrated that all the major SCFAs including acetic acid, butyric acid, propanoic acid, and some SCFA-producing bacteria taxa, such as genera Faecalibacterium and Rose bur…”
ResultMacia, L., Tan, J., Vieira, A. T., Leach, K., Stanley, D., Luong, S., Maruya, M., Ian McKenzie, C., Hijikata, A., Wong, C., et al. (2015) · Nature Communications · doi:10.1038/ncomms7734 · Cited by 1,439 · cited 1×
“Moreover, SCFAs, especially butyrate, are kno wn to exert immunomodulation effects via expanding the pool of intestinal regulatory T cells,(38) and maintain epithelial homeostasis through the production of interleukin (IL)-18 via inflammasome activation.(39) The fecal level of SCFAs and gut bacteria ferment fibers tha…”
BackgroundMicrobial bile acid metabolites modulate gut RORγ+ regulatory T cell homeostasis
Song, X., Sun, X., Oh, S. F., Wu, M., Zhang, Y., Zheng, W., Geva-Zatorsky, N., Jupp, R., Mathis, D., Benoist, C., et al. (2020) · Nature · doi:10.1038/s41586-019-1865-0 · Cited by 1,024 · cited 1×
“Alteration in BA metabolism can cause membrane damage to both microbial cells and the intestinal barrier, and impair the development of colo nic RORγ regulatory T cells thereby promoting intestinal inflammation.(46,47) Taken together, our da ta indicate that gut microbiota dysbiosis may contribute to the inflammation…”
BackgroundBile Acid Is a Host Factor That Regulates the Composition of the Cecal Microbiota in Rats
Islam, K. B. M. S., Fukiya, S., Hagio, M., Fujii, N., Ishizuka, S., Ooka, T., Ogura, Y., Hayashi, T., & Yokota, A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.046 · Cited by 918
Cited by
Bile acids as modulators of gut microbiota composition and function
Larabi, A. B., Masson, H. L. P., & Bäumler, A. J. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2172671 · Cited by 401
New insights into microbial bile salt hydrolases: from physiological roles to potential applications
Dong, Z., Yang, S., Tang, C., Li, D., Kan, Y., & Yao, L. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1513541 · Cited by 64
“Gut microbiota-derived BSH activity act as a serum metabolomic biomarker, and its changes have been linked to many human diseases, such as hepatobiliary disease (Parasar et al., 2019), Crohn’s disease (Wang Y. et al., 2021), and non-obese liver fibrosis (Lee et al., 2020).”
Self-citationWang, X., Shang, Y., Wei, Q., Wu, X., Dou, H., Zhang, H., Zhou, S., Sha, W., Sun, G., Ma, S., et al. (2022) · Microbial Ecology · doi:10.1007/s00248-021-01806-8 · Cited by 36
Zhao, S., Dien, B. S., Lindemann, S. R., & Chen, M.-H. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118418 · Cited by 16
Metadata
- Authors
- Wang, Y., Gao, X., Zhang, X., Xiao, F., Hu, H., Li, X., Dong, F., Sun, M., Xiao, Y., Ge, T., Li, D., Yu, G., Liu, Z., & Zhang, T.
- Venue
- Gut Microbes
- Publisher
- Informa UK Limited
- Published
- 2021-01
- Volume
- 13
- Issue
- 1
- Pages
- 1-18
- ISSN
- 1949-0976 (ISSN-L)
- 1949-0984
- OpenAlex
- W3118475270
- Cited by
- 109
- References
- 13
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease. https://app.cochat.ai/papers/10.1080/19490976.2020.1865708
- The paper
- Wang, Y., Gao, X., Zhang, X., Xiao, F., Hu, H., Li, X., Dong, F., Sun, M., Xiao, Y., Ge, T., Li, D., Yu, G., Liu, Z., & Zhang, T. (2021). Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease. Gut Microbes. https://doi.org/10.1080/19490976.2020.1865708
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.